Terms: = Sarcomas AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2 AND Treatment
5 results:
1. [Mesenchymal tumors and tumor-like lesions of the gastrointestinal tract: an overview].
Agaimy A
Pathologe; 2022 Feb; 43(1):31-44. PubMed ID: 34919183
[TBL] [Abstract] [Full Text] [Related]
2. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract] [Full Text] [Related]
3. CD30 and ALK combination therapy has high therapeutic potency in ranbp2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract] [Full Text] [Related]
4. Epithelioid Inflammatory Myofibroblastic Sarcoma of the Ovary With RANB2-ALK Fusion: Report of a Case.
Fang H; Langstraat CL; Visscher DW; Folpe AL; Schoolmeester JK
Int J Gynecol Pathol; 2018 Sep; 37(5):468-472. PubMed ID: 28787324
[TBL] [Abstract] [Full Text] [Related]
5. A case report of epithelioid inflammatory myofibroblastic sarcoma with ranbp2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract] [Full Text] [Related]
